Publications by authors named "Franca Patrizi"
Article Synopsis
- Bile duct injury (BDI) is a serious complication following cholecystectomy, with incidences ranging from 0.4% to 1.5%, potentially leading to significant long-term health issues for patients.
- Early recognition of BDIs, whether during surgery or soon after, is crucial for effective treatment, as delayed diagnoses can complicate management and outcomes.
- The 2020 World Society of Emergency Surgery (WSES) guidelines provide evidence-based recommendations on preventing, diagnosing, and managing BDIs, covering risk reduction strategies, classification, intraoperative management, and postoperative care.
Iatrogenic colonoscopy perforation (ICP) is a severe complication that can occur during both diagnostic and therapeutic procedures. Although 45-60% of ICPs are diagnosed by the endoscopist while performing the colonoscopy, many ICPs are not immediately recognized but are instead suspected on the basis of clinical signs and symptoms that occur after the endoscopic procedure. There are three main therapeutic options for ICPs: endoscopic repair, conservative therapy, and surgery.
View Article and Find Full Text PDFNovel therapeutic approaches to the treatment of chronic abdominal visceral pain.
ScientificWorldJournal
April 2006
Chronic abdominal visceral pain (CAVP) has a significant clinical impact and represents one of the most frequent and debilitating disorders in the general population. It also leads to a significant economic burden due to workdays lost, reduced productivity, and long-term use of medications with their associated side effects. Despite the availability of several therapeutic options, the management of patients with CAVP is often inadequate, resulting in frustration for both patients and physicians.
View Article and Find Full Text PDFManagement of HCV infection and related liver disease with treatment currently available lead to a sustained virological response in 20% of patients using interferon (IFN)-alpha mono-therapy and approximately 40-45% in those on combination therapy with ribavirin.The aim of the present investigation was to compare the effect of consensus interferon alphacon-1 (C-IFN), and IFN-alpha 2b plus ribavirin, in patients relapsing after treatment with interferon alone. A total of 112 randomised patients with relapsing HCV infection (M/F=53/59), were treated for 24 weeks with: (A) IFN-alpha 2b starting with 5/6MU/day till negativity of HCV-RNA followed by 3MU every other day, plus ribavirin 15mg/kg/day (n=34); (B) C-IFN 9microg/day (n=40); (C) ursodeoxycholic acid (UDCA; sodium salt) 450mg/day (n=37).
View Article and Find Full Text PDFArticle Synopsis
- Study aimed to improve hepatitis C treatment in older patients using amantadine (AH) alongside interferon (IFN) due to IFN's side effects.
- Out of 165 patients over 65 who had not responded to previous IFN treatments, three groups were formed: Group A received only AH, Group B received IFN alone, and Group C received both AH and IFN.
- Results showed that Group C had the highest percentage of patients achieving normal ALT levels and negative HCV-RNA, suggesting that the combination treatment was more effective and reduced side effects from IFN.